BofA Securities Raises Price Target on Alamar Biosciences

BofA Securities updated its outlook on Alamar Biosciences, raising the 12-month price target for the company's stock to $35 from the previous $31. This adjustment follows the company's recent operational developments and market performance. The change reflects the firm's updated valuation assessment of the life sciences company.